Strategies for the Development of Conotoxins as New Therapeutic Leads

被引:19
作者
Brady, Ryan M. [1 ]
Baell, Jonathan B. [1 ]
Norton, Raymond S. [1 ]
机构
[1] Monash Univ, Monash Inst Pharmaceut Sci, Parkville, Vic 3052, Australia
来源
MARINE DRUGS | 2013年 / 11卷 / 07期
基金
英国医学研究理事会; 澳大利亚研究理事会;
关键词
peptide toxin; peptidomimetic; ion channel; pain; cone snail; RING-CLOSING METATHESIS; CALCIUM-CHANNEL BLOCKER; NEUROPEPTIDE-Y ANALOGS; OMEGA-CONOTOXIN; ALPHA-CONOTOXIN; ACETYLCHOLINE-RECEPTOR; BIOLOGICAL EVALUATION; NONPEPTIDE MIMETICS; STRUCTURAL-CHARACTERIZATION; IMPROVE STABILITY;
D O I
10.3390/md11072293
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Peptide toxins typically bind to their target ion channels or receptors with high potency and selectivity, making them attractive leads for therapeutic development. In some cases the native peptide as it is found in the venom from which it originates can be used directly, but in many instances it is desirable to truncate and/or stabilize the peptide to improve its therapeutic properties. A complementary strategy is to display the key residues that make up the pharmacophore of the peptide toxin on a non-peptidic scaffold, thereby creating a peptidomimetic. This review exemplifies these approaches with peptide toxins from marine organisms, with a particular focus on conotoxins.
引用
收藏
页码:2293 / 2313
页数:21
相关论文
共 123 条
[1]   Converting a peptide into a drug: Strategies to improve stability and bioavailability [J].
Adessi, C ;
Soto, C .
CURRENT MEDICINAL CHEMISTRY, 2002, 9 (09) :963-978
[2]  
Adessi C, 2004, Front Med Chem, V1, P513, DOI [10.2174/1567204043396622, DOI 10.2174/1567204043396622]
[3]   Marine toxins as sources of drug leads [J].
Alewood, P ;
Hopping, G ;
Armishaw, C .
AUSTRALIAN JOURNAL OF CHEMISTRY, 2003, 56 (08) :769-774
[4]   An oral cyclic peptide drug to reverse kidney fibrosis? [J].
Susan J. Allison .
Nature Reviews Nephrology, 2012, 8 (4) :193-193
[5]   ω-Conotoxin GVIA mimetics based on an anthranilamide core: Effect of variation in ammonium side chain lengths and incorporation of fluorine [J].
Andersson, Asa ;
Baell, Jonathan B. ;
Duggan, Peter J. ;
Graham, Janease E. ;
Lewis, Richard J. ;
Lumsden, Natalie G. ;
Tranberg, C. Elisabet ;
Tuck, Kellie L. ;
Yang, Aijun .
BIOORGANIC & MEDICINAL CHEMISTRY, 2009, 17 (18) :6659-6670
[6]   α-selenoconotoxins, a new class of potent α7 neuronal nicotinic receptor antagonists [J].
Armishaw, Christopher J. ;
Daly, Norelle L. ;
Nevin, Simon T. ;
Adams, David J. ;
Craik, David J. ;
Alewood, Paul F. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (20) :14136-14143
[7]   Molecular recognition of protein-ligand complexes: Applications to drug design [J].
Babine, RE ;
Bender, SL .
CHEMICAL REVIEWS, 1997, 97 (05) :1359-1472
[8]   Synthesis and biological evaluation of nonpeptide mimetics of co-conotoxin GVIA [J].
Baell, JB ;
Duggan, PJ ;
Forsyth, SA ;
Lewis, RJ ;
Lok, YP ;
Schroeder, CI .
BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (15) :4025-4037
[9]   Design and synthesis of type-III mimetics of ω-conotoxin GVIA [J].
Baell, JB ;
Forsyth, SA ;
Gable, RW ;
Norton, RS ;
Mulder, RJ .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2001, 15 (12) :1119-1136
[10]   Synthesis and biological evaluation of anthranilamide-based non-peptide mimetics of ω-conotoxin GVIA [J].
Baell, Jonathan B. ;
Duggan, Peter J. ;
Forsyth, Stewart A. ;
Lewis, Richard J. ;
Lok, Y. Phei ;
Schroeder, Christina I. ;
Shepherd, Nicholas E. .
TETRAHEDRON, 2006, 62 (31) :7284-7292